8-K current report · filed Aug 11, 2026

Neurogene Inc. (NGNE) 8-K Current Report: August 11, 2026

Item EX-99.2Item EX-99.1Item 2.02NGNE overview

Short answer

Neurogene Inc. (NGNE) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.

Neurogene Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Updated corporate presentation provides investors with refreshed company and pipeline information
  • Full financial figures and management commentary in Exhibit 99.1
  • Strategic and clinical updates in Exhibit 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1/2 efficacy signal strengthened: 100% of participants improved on CGI-I and gained milestones, averaging 4.7 each through 30 months
  • NGN-401 safety remained generally well-tolerated at 1E15 vg across 35 participants, supporting continued registrational development
  • Embolden trial dosing completed for 25 participants, with topline data expected in 2H 2027, the key clinical catalyst
  • PPQ campaign initiated for potential BLA submission, with manufacturing qualification runs targeted for completion by year-end 2026
  • Approximately $134.8M net offering proceeds lifted pro forma liquidity to $360.2M, extending runway into 1Q 2029 despite quarterly net loss of $34.5M

Item EX-99.2 · Exhibit EX-99.2

  • Embolden registrational trial fully dosed with 25 participants, supporting a single-trial BLA strategy for females aged ≥3 years
  • Phase 1/2 data: 100% of 10 participants gained milestones, 80% met the composite responder definition, with 4.7 average gains
  • Durability signal strengthened: milestone gains increased 95% from 6 to 12 months and 147% from 6 to ≥12 months
  • Safety remains favorable at 1E15 vg, with no treatment-related serious adverse events, dose-limiting toxicities, or milestone losses
  • Key catalysts: BLA-enabling PPQ runs expected by year-end 2026 and Embolden topline data anticipated in 2H 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Neurogene Inc. 8-K filings

Get the next NGNE 8-K as it lands

Follow NGNE for push alerts, or ask the research agent what this filing means.